Acute Coronary Syndrome Market Trends
Acute Coronary Syndrome Market Research Report by Type (Unstable Angina, Nstemi), by Diagnosis (Blood Tests, Imaging, Stress Test), Treatment (Medication, Surgery), End-User (Hospitals & Clinics, Diagnostic Centers) - Forecast Till 2032

Market Summary
The Global Acute Coronary Syndrome Market is projected to experience substantial growth from 8.45 USD Billion in 2024 to 17.7 USD Billion by 2035.
Key Market Trends & Highlights
Acute Coronary Syndrome Key Trends and Highlights
- The market is expected to grow at a compound annual growth rate (CAGR) of 6.97% from 2025 to 2035.
- By 2035, the market valuation is anticipated to reach 17.7 USD Billion, indicating robust expansion.
- In 2024, the market is valued at 8.45 USD Billion, reflecting a strong foundation for future growth.
- Growing adoption of advanced diagnostic technologies due to increasing prevalence of cardiovascular diseases is a major market driver.
Market Size & Forecast
2024 Market Size | 8.45 (USD Billion) |
2035 Market Size | 17.7 (USD Billion) |
CAGR (2025-2035) | 6.97% |
Largest Regional Market Share in 2024 | latin_america) |
Major Players
Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), AstraZeneca (U.K), Amgen Inc. (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.K), Sanofi (Paris), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.)
Market Trends
The increasing prevalence of risk factors such as obesity and diabetes is likely to drive the demand for innovative treatments and preventive measures in the Acute Coronary Syndrome market.
Centers for Disease Control and Prevention (CDC)
Acute Coronary Syndrome Market Market Drivers
Market Trends and Projections
Growing Awareness and Education
The rising awareness regarding cardiovascular health and the importance of early detection of acute coronary syndrome is driving the Global Acute Coronary Syndrome Market Industry. Educational campaigns aimed at both healthcare professionals and the general public are increasingly emphasizing the risk factors and symptoms associated with acute coronary syndrome. This heightened awareness is leading to earlier diagnosis and treatment, which is crucial for improving patient outcomes. As more individuals recognize the signs and seek medical attention promptly, the demand for related healthcare services and products is expected to surge, further stimulating market growth.
Increased Healthcare Expenditure
Rising healthcare expenditure across various nations is a crucial factor propelling the Global Acute Coronary Syndrome Market Industry. Governments and private sectors are investing more in healthcare infrastructure, leading to enhanced access to diagnostic and therapeutic services for acute coronary syndrome. For example, countries are allocating substantial budgets to cardiovascular health initiatives, which include screening programs and public awareness campaigns. This increased funding is likely to facilitate the adoption of advanced treatment options, thereby contributing to a projected compound annual growth rate of 6.97% from 2025 to 2035, as the market adapts to the growing demand for effective cardiovascular care.
Regulatory Support and Guidelines
Supportive regulatory frameworks and clinical guidelines are fostering growth in the Global Acute Coronary Syndrome Market Industry. Regulatory bodies are increasingly endorsing new treatment protocols and technologies that enhance patient care. For instance, updated clinical guidelines from health organizations promote the use of novel therapies and interventions for acute coronary syndrome, ensuring that healthcare providers are equipped with the latest evidence-based practices. This regulatory backing not only boosts confidence among healthcare professionals but also encourages investment in research and development, thereby contributing to the overall expansion of the market.
Advancements in Medical Technology
Technological innovations in diagnostics and treatment methodologies are significantly influencing the Global Acute Coronary Syndrome Market Industry. The development of advanced imaging techniques, such as cardiac MRI and CT angiography, enhances the accuracy of diagnosis, allowing for timely interventions. Moreover, the introduction of minimally invasive surgical procedures and novel pharmacological therapies contributes to improved patient outcomes. As these technologies evolve, they are expected to drive market growth, with projections indicating a market value of 17.7 USD Billion by 2035. This trend reflects the industry's commitment to integrating cutting-edge technology in the management of acute coronary syndrome.
Rising Prevalence of Cardiovascular Diseases
The increasing incidence of cardiovascular diseases globally is a primary driver for the Global Acute Coronary Syndrome Market Industry. As lifestyle-related factors such as obesity, sedentary behavior, and unhealthy diets become more prevalent, the number of individuals at risk for acute coronary syndrome rises. For instance, data indicates that cardiovascular diseases account for approximately 31% of all global deaths, underscoring the urgent need for effective management and treatment options. This growing health crisis is projected to elevate the market value to 8.45 USD Billion in 2024, highlighting the industry's response to this pressing health challenge.
Market Segment Insights
Regional Insights
Key Companies in the Acute Coronary Syndrome Market market include





Industry Developments
BioCardia, Inc. stated in October 2021 that the first patient in their CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for refractory angina has been treated in Acute Coronary Syndrome.
The Independent Data Monitoring Committee approved XyloCor Therapeutics' Phase 2 trial of XC001 for refractory angina in July 2021. (IDMC). The greatest dose was given to three people with refractory angina in this study.
Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Future Outlook
Acute Coronary Syndrome Market Future Outlook
The Global Acute Coronary Syndrome Market is projected to grow at a 6.97% CAGR from 2024 to 2035, driven by advancements in treatment technologies and increasing prevalence of cardiovascular diseases.
New opportunities lie in:
- Invest in AI-driven diagnostic tools to enhance early detection of Acute Coronary Syndrome.
- Develop personalized medicine approaches to improve treatment efficacy and patient outcomes.
- Expand telemedicine services for remote monitoring and management of cardiovascular patients.
By 2035, the market is expected to exhibit robust growth, reflecting advancements in care and increasing global demand.
Market Segmentation
Intended Audience
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Government and Private Laboratories
- Biotechnological Institutes
- Pharmaceutical Companies
Recent Development
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Government and Private Laboratories
- Biotechnological Institutes
- Pharmaceutical Companies
Acute Coronary Syndrome Market Key Players
- Merck & Co., Inc. (U.S.)
- Novartis AG (Switzerland)
- Sanofi (Paris)
- GlaxoSmithKline Plc. (U.K)
- Eli Lilly and Company (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED. (Japan)
- Bayer AG (Germany)
- Amgen Inc. (U.S.)
- AstraZeneca (U.K)
- AbbVie Inc. (U.S.)
- Portola Pharmaceuticals, Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Johnson & Johnson Services, Inc. (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Government and Private Laboratories
- Biotechnological Institutes
- Pharmaceutical Companies
Report Scope
Report Attribute/Metric | Details |
Market Size 2022 | NA (USD Billion) |
Market Size 2023 | NA (USD Billion) |
Market Size 2032 | 15.2 (USD Billion) |
Compound Annual Growth Rate (CAGR) | 5.3 % (2024- 2032) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Base Year | 2022 |
Market Forecast Period | 2023 - 2032 |
Historical Data | 2019 - 2022 |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), AstraZeneca (U.K), Amgen Inc. (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.K), Sanofi (Paris), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.) |
Key Market Opportunities | Increasing healthcare expenditure increasing availability of funds for research |
Key Market Drivers | The increasing prevalence of coronary heart disease Growing geriatric population Growing obese population |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
At what CAGR is the Acute Coronary Syndrome Market predicted to grow during the forecast period?
Acute Coronary Syndrome Market is projected to grow at a 5.3% CAGR between 2023-2032.
Which region is expected to lead the Acute Coronary Syndrome Market?
The Americas is expected to lead the Acute Coronary Syndrome Market.
What are different end users of Acute Coronary Syndrome Market?
Different end users of Acute Coronary Syndrome Market include academic institutes, diagnostic centers, hospitals and clinics, and others.
What are the key factors driving the Acute Coronary Syndrome Market?
Growing obese population and rising prevalence of diabetes is adding market growth.
Which factors may limit the Acute Coronary Syndrome Market growth?
High cost and lack of awareness may limit market growth.
-
Chapter 1. Report Prologue
-
Chapter 2. Market Introduction
- Definition
-
Scope of the Study
- Research
-
Objective
-
Assumptions
- Limitations
-
Assumptions
-
Chapter 3. Research
-
Methodology
- Introduction
- Primary Research
- Secondary
-
research
- Market Size Estimation
-
Chapter 4. Market Dynamics
-
Drivers
- Restraints
- Opportunities
- Challenges
-
Macroeconomic Indicators
- Technology Trends & Assessment
-
Chapter
-
Market Factor Analysis
- Porter’s Five Forces Analysis
-
Bargaining Power of Suppliers
- Bargaining Power of Buyers
-
Threat of New Entrants
-
Threat of Substitutes
- Intensity of
-
Threat of Substitutes
-
Rivalry
- Value Chain Analysis
- Investment Feasibility Analysis
- Pricing Analysis
-
Chapter 6. Global Acute Coronary Syndrome Market,
-
by Type
- Introduction
- Unstable angina
-
Market Estimates &
-
Forecast, 2023–2032
- ST-Elevation Myocardial Infarction (STEMI)
-
Market Estimates & Forecast, 2023–2032
- Non-ST-Elevation Myocardial
-
Infarction (NSTEMI)
-
Market Estimates & Forecast, 2023–2032
-
Chapter
-
Global Acute Coronary Syndrome Market, by Diagnosis
- Introduction
- Blood Tests
-
Market Estimates & Forecast, 2023–2032
-
Imaging
-
Market Estimates & Forecast, 2023–2032
- Myocardial
-
Perfusion Imaging (MPI)
- Computerized Tomography (CT) Angiogram
-
Echocardiogram
-
Coronary Angiogram
- Others
- Stress Test
- Others
-
Coronary Angiogram
-
Chapter 8. Global Acute Coronary Syndrome Market, by Treatment
- Introduction
- Medication
-
Market Estimates & Forecast, 2023–2032
- Thrombolytics
-
Market Estimates & Forecast, 2023–2032
-
Nitroglycerin
-
Market Estimates & Forecast, 2023–2032
- Antiplatelet
-
Drugs
-
Market Estimates & Forecast, 2023–2032
-
Aspirin
- Clopidogrel
-
Aspirin
-
Beta Blockers
-
Market Estimates & Forecast, 2023–2032
-
Metoprolol
-
Nadolol
- Others
- Statins
-
Nadolol
-
Market
-
Estimates & Forecast, 2023–2032
- Atorvastatin
-
Simvastatin
-
Others
- Others
- Surgery
-
Others
-
Market Estimates
-
& Forecast, 2023–2032
- Angioplasty & Stenting
-
Coronary Bypass Surgery
- Others
-
Chapter 9. Global Acute Coronary
-
Syndrome Market, by End-User
- Introduction
- Hospital & Clinics
-
Market Estimates & Forecast, 2023–2032
- Diagnostic Centers
-
Market Estimates & Forecast, 2023–2032
- Academic Institutes
-
Market Estimates & Forecast, 2023–2032
- Others
-
Chapter
-
Global Acute Coronary Syndrome Market, by Region
- Introduction
-
America
-
North America
- U.S.
-
North America
-
South America
-
Europe
- Western Europe
- Eastern Europe
-
Asia Pacific
- Japan
- China
- India
- Australia
-
Europe
-
Republic of Korea
- Rest of Asia Pacific
- The Middle East &
-
Africa
-
United Arab Emirates
- Saudi Arabia
- Oman
- Kuwait
- Qatar
- Rest of the Middle East & Africa
-
United Arab Emirates
-
Chapter 11. Company Landscape
- Introduction
- Market Share
-
Analysis
-
Key Development & Strategies
- Key Developments
-
Key Development & Strategies
-
Chapter 12 Company Profiles
- Boehringer Ingelheim International
-
GmbH
-
Company Overview
- Type Overview
- Financials
- Key Developments
- SWOT Analysis
- Johnson & Johnson
-
Company Overview
-
Services, Inc.
-
Company Overview
- Type Overview
-
Company Overview
-
Financial Overview
-
Key Developments
- SWOT Analysis
-
Teva Pharmaceutical Industries Ltd.
- Company Overview
-
Key Developments
-
Type Overview
-
Financial Overview
- Key Development
-
Financial Overview
-
SWOT Analysis
-
Portola Pharmaceuticals, Inc.
- Company Overview
- Type/Business Segment Overview
- Financial Overview
- Key Development
- SWOT Analysis
- AbbVie Inc.
-
Portola Pharmaceuticals, Inc.
-
Company Overview
-
Type Overview
- Financial overview
- Key Developments
- SWOT Analysis
- AstraZeneca
-
Type Overview
-
Company Overview
-
Type Overview
- Financial Overview
- Key Developments
- SWOT Analysis
- Amgen Inc.
-
Type Overview
-
Overview
-
Type Overview
- Financials
- Key Developments
- SWOT Analysis
-
Bayer AG
- Overview
-
Type Overview
-
Type Overview
-
Financials
- Key Developments
-
Financials
-
SWOT Analysis
-
DAIICHI SANKYO COMPANY, LIMITED.
- Overview
- Type Overview
- Financials
- Key Developments
- SWOT Analysis
-
Eli Lilly and Company
- Overview
- Type Overview
- Financials
- Key Developments
- SWOT Analysis
-
GlaxoSmithKline Plc.
- Overview
- Type Overview
- Financials
- Key Developments
- SWOT Analysis
-
Sanofi
- Overview
-
DAIICHI SANKYO COMPANY, LIMITED.
-
Type Overview
-
Financials
- Key Developments
-
Financials
-
SWOT Analysis
-
Novartis AG
- Overview
- Type Overview
- Financials
- Key Developments
- SWOT Analysis
-
Merck & Co., Inc.
- Overview
- Type Overview
- Financials
- Key Developments
- SWOT Analysis
- Others
-
Novartis AG
-
Chapter 13 MRFR Conclusion
- Key Findings
-
From CEO’s View Point
- Unmet Needs of the Market
- Key
-
Companies to Watch
- Prediction of Acute Coronary Syndrome Market
-
Chapter
-
Appendix
-
Synopsis, 2023–2032
-
& Forecast, 2023–2032, (USD Million)
-
Syndrome Market, by Region, 2023–2032, (USD Million)
-
Coronary Syndrome Market, by Type, 2023–2032, (USD Million)
-
Acute Coronary Syndrome Market, by Diagnosis, 2023–2032, (USD Million)
-
(USD Million)
-
(USD Million
-
–2032, (USD Million)
-
Market, by Diagnosis, 2023–2032, (USD Million)
-
Acute Coronary Syndrome Market, by Treatment, 2023–2032, (USD Million)
-
(USD Million)
-
(USD Million)
-
(USD Million)
-
(USD Million)
-
(USD Million)
-
(USD Million)
-
–2032, (USD Million)
-
by Treatment, 2023–2032, (USD Million)
-
Syndrome Market, by End-User, 2023–2032, (USD Million)
-
America Acute Coronary Syndrome Market, by Type, 2023–2032, (USD Million)
-
(USD Million)
-
–2032, (USD Million)
-
Market, by End-User, 2023–2032, (USD Million)
-
Syndrome Market, by Type, 2023–2032, (USD Million)
-
Coronary Syndrome Market, by Diagnosis, 2023–2032, (USD Million)
-
Europe Acute Coronary Syndrome Market, by Treatment, 2023–2032, (USD Million)
-
(USD Million)
-
–2032, (USD Million)
-
Market, by Diagnosis, 2023–2032, (USD Million)
-
Acute Coronary Syndrome Market, by Treatment, 2023–2032, (USD Million)
-
(USD Million)
-
–2032, (USD Million)
-
Market, by Diagnosis, 2023–2032, (USD Million)
-
Acute Coronary Syndrome Market, by Treatment, 2023–2032, (USD Million)
-
(USD Million)
-
–2032, (USD Million)
-
Market, by Diagnosis, 2023–2032, (USD Million)
-
Acute Coronary Syndrome Market, by Treatment, 2023–2032, (USD Million)
-
(USD Million)
-
Market, by Type, 2023–2032, (USD Million)
-
Africa Acute Coronary Syndrome Market, by Diagnosis, 2023–2032, (USD Million)
-
–2032, (USD Million)
-
Coronary Syndrome Market, by End-User, 2023–2032, (USD Million)
-
LIST
-
OF FIGURES
-
Acute Coronary Syndrome Market
-
Syndrome Market
-
Global Acute Coronary Syndrome Market Share, by End-User, 2023
-
Acute Coronary Syndrome Market Share, by Region, 2023
-
Acute Coronary Syndrome Market Share, by Country, 2023
-
Coronary Syndrome Market Share, by Country, 2023
-
Coronary Syndrome Market Share, by Country, 2023
-
& Africa Acute Coronary Syndrome Market Share, by Country, 2023
-
Global Acute Coronary Syndrome Market: Company Share Analysis, 2023 (%)
-
Boehringer Ingelheim International GmbH: Key Financials
-
Ingelheim International GmbH: Segmental Revenue
-
International GmbH: Geographical Revenue
-
Inc.: Key Financials
-
Revenue
-
Pharmaceutical Industries Ltd.: Segmental Revenue
-
Industries Ltd.: Geographical Revenue
-
Key Financials
-
Inc.: Key Financials
-
AbbVie Inc.: Geographical Revenue
-
Revenue
-
Revenue
-
Key Financials
-
Geographical Revenue
-
SANKYO COMPANY, LIMITED.: Geographical Revenue
-
Key Financials
-
Eli Lilly and Company: Geographical Revenue
-
Key Financials
-
GlaxoSmithKline plc.: Geographical Revenue
-
Revenue
-
Co., Inc.: Key Financials
Acute Coronary Syndrome Market Segmentation
Market Segmentation Overview
- Detailed segmentation data will be available in the full report
- Comprehensive analysis by multiple parameters
- Regional and country-level breakdowns
- Market size forecasts by segment

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment